Upgrade to SI Premium - Free Trial

Guggenheim Reiterates Buy Rating on Pfizer (PFE)

October 13, 2026 7:17 AM
Guggenheim analyst Vamil Divan reiterated a Buy rating and $31.00 price target on Pfizer (NYSE: PFE).The analyst commented: "We are ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments